SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
An activist holds a placard opposing any post-Brexit U.S. market access to Britain's National Health Service (NHS) during a demonstration in Trafalgar Square, London. (Photo: David Cliff/SOPA Images/LightRocket via Getty Images)
Documents Reveal 'Toxic Trump-Johnson Deal' Post-Brexit Would Allow US Pharma Industry to Send NHS Drug Prices Skyrocketing
"A Labour government will stop our NHS being sold off in a toxic trade deal with Trump," Labour leader Jeremy Corbyn said.
Dec 03, 2019
Brexit and Tory critics in the U.K. on Wednesday called on voters to reject the Conservatives in the upcoming general election in light of new confirmation that U.S. pharmaceutical companies would be given free reign to drive up drug prices in a post-Brexit trade deal should the Conservatives retain control of the government.
Documents obtained Tuesday by the Daily Mirror reveal that the U.S. pharmaceutical industry is lobbying trade negotiators to allow for an open drug market in the U.K. in the potential trade deal President Donald Trump plans to forge with the Tories if Prime Minister Boris Johnson and his party win on Dec. 12.
"Boris Johnson has put our NHS up for sale. It's time to save the NHS from a U.S. trade deal."
--The Labour Party
The "predatory" industry, as the Mirror described Big Pharma, is hoping for one-on-one negotiations with the U.K. after Brexit, away from the E.U., believing the U.K. on its own will be likely to allow U.S. companies to set drug prices.
"Concerns about potential impacts on Britain's National Health Service are being aired," reads the document, titled Services Priorities for a Future U.S.-U.K. Trade Agreement. "It should prove easier to overcome these challenges with the UK as an individual negotiating partner."
Supporters of the National Health Service (NHS), which fixes drug prices based on their value through the National Institute for Health and Care Excellence (NICE) and currently pays PS18 billion ($23 billion) per year for medications, warned that a Trump-Johnson deal would send prices skyrocketing, drastically cutting NHS's funding for doctors and nurses.
"Today's revelations are yet more evidence that U.S. big pharma companies are lining up to cash-in on a toxic Johnson-Trump deal," said Shadow Health Secretary Jonathan Ashworth. "These mega corporations want us to pay more for medicine and the proposed U.S.-U.K. deal could draw PS500 million [$655 million] a week from our NHS."
"A Labour government will stop our NHS being sold off in a toxic trade deal with Trump," Labour Party leader Jeremy Corbyn tweeted.
U.S. control over drug prices "would hit the Scottish NHS incredibly hard," said Hannah Bardell, a Scottish National Party politician.
The Mirror reported on the documents shortly after Trump said at the NATO summit in London that the U.S. had no interest in changing how NHS operates as part of a post-Brexit trade deal.
Kevin Maguire, associate editor of the Mirror, tweeted the new evidence shows "Trump's lying, again."
Johnson's secretary of state, Dominic Raab, also confirmed Tuesday that the U.S. would be given control over life-saving drug prices in the event of a deal, saying, "The Americans will take their decisions."
"Boris Johnson has put our NHS up for sale," tweeted the Labour Party. "It's time to save the NHS from a U.S. trade deal. You can't trust the Tories with our NHS."
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Brexit and Tory critics in the U.K. on Wednesday called on voters to reject the Conservatives in the upcoming general election in light of new confirmation that U.S. pharmaceutical companies would be given free reign to drive up drug prices in a post-Brexit trade deal should the Conservatives retain control of the government.
Documents obtained Tuesday by the Daily Mirror reveal that the U.S. pharmaceutical industry is lobbying trade negotiators to allow for an open drug market in the U.K. in the potential trade deal President Donald Trump plans to forge with the Tories if Prime Minister Boris Johnson and his party win on Dec. 12.
"Boris Johnson has put our NHS up for sale. It's time to save the NHS from a U.S. trade deal."
--The Labour Party
The "predatory" industry, as the Mirror described Big Pharma, is hoping for one-on-one negotiations with the U.K. after Brexit, away from the E.U., believing the U.K. on its own will be likely to allow U.S. companies to set drug prices.
"Concerns about potential impacts on Britain's National Health Service are being aired," reads the document, titled Services Priorities for a Future U.S.-U.K. Trade Agreement. "It should prove easier to overcome these challenges with the UK as an individual negotiating partner."
Supporters of the National Health Service (NHS), which fixes drug prices based on their value through the National Institute for Health and Care Excellence (NICE) and currently pays PS18 billion ($23 billion) per year for medications, warned that a Trump-Johnson deal would send prices skyrocketing, drastically cutting NHS's funding for doctors and nurses.
"Today's revelations are yet more evidence that U.S. big pharma companies are lining up to cash-in on a toxic Johnson-Trump deal," said Shadow Health Secretary Jonathan Ashworth. "These mega corporations want us to pay more for medicine and the proposed U.S.-U.K. deal could draw PS500 million [$655 million] a week from our NHS."
"A Labour government will stop our NHS being sold off in a toxic trade deal with Trump," Labour Party leader Jeremy Corbyn tweeted.
U.S. control over drug prices "would hit the Scottish NHS incredibly hard," said Hannah Bardell, a Scottish National Party politician.
The Mirror reported on the documents shortly after Trump said at the NATO summit in London that the U.S. had no interest in changing how NHS operates as part of a post-Brexit trade deal.
Kevin Maguire, associate editor of the Mirror, tweeted the new evidence shows "Trump's lying, again."
Johnson's secretary of state, Dominic Raab, also confirmed Tuesday that the U.S. would be given control over life-saving drug prices in the event of a deal, saying, "The Americans will take their decisions."
"Boris Johnson has put our NHS up for sale," tweeted the Labour Party. "It's time to save the NHS from a U.S. trade deal. You can't trust the Tories with our NHS."
Brexit and Tory critics in the U.K. on Wednesday called on voters to reject the Conservatives in the upcoming general election in light of new confirmation that U.S. pharmaceutical companies would be given free reign to drive up drug prices in a post-Brexit trade deal should the Conservatives retain control of the government.
Documents obtained Tuesday by the Daily Mirror reveal that the U.S. pharmaceutical industry is lobbying trade negotiators to allow for an open drug market in the U.K. in the potential trade deal President Donald Trump plans to forge with the Tories if Prime Minister Boris Johnson and his party win on Dec. 12.
"Boris Johnson has put our NHS up for sale. It's time to save the NHS from a U.S. trade deal."
--The Labour Party
The "predatory" industry, as the Mirror described Big Pharma, is hoping for one-on-one negotiations with the U.K. after Brexit, away from the E.U., believing the U.K. on its own will be likely to allow U.S. companies to set drug prices.
"Concerns about potential impacts on Britain's National Health Service are being aired," reads the document, titled Services Priorities for a Future U.S.-U.K. Trade Agreement. "It should prove easier to overcome these challenges with the UK as an individual negotiating partner."
Supporters of the National Health Service (NHS), which fixes drug prices based on their value through the National Institute for Health and Care Excellence (NICE) and currently pays PS18 billion ($23 billion) per year for medications, warned that a Trump-Johnson deal would send prices skyrocketing, drastically cutting NHS's funding for doctors and nurses.
"Today's revelations are yet more evidence that U.S. big pharma companies are lining up to cash-in on a toxic Johnson-Trump deal," said Shadow Health Secretary Jonathan Ashworth. "These mega corporations want us to pay more for medicine and the proposed U.S.-U.K. deal could draw PS500 million [$655 million] a week from our NHS."
"A Labour government will stop our NHS being sold off in a toxic trade deal with Trump," Labour Party leader Jeremy Corbyn tweeted.
U.S. control over drug prices "would hit the Scottish NHS incredibly hard," said Hannah Bardell, a Scottish National Party politician.
The Mirror reported on the documents shortly after Trump said at the NATO summit in London that the U.S. had no interest in changing how NHS operates as part of a post-Brexit trade deal.
Kevin Maguire, associate editor of the Mirror, tweeted the new evidence shows "Trump's lying, again."
Johnson's secretary of state, Dominic Raab, also confirmed Tuesday that the U.S. would be given control over life-saving drug prices in the event of a deal, saying, "The Americans will take their decisions."
"Boris Johnson has put our NHS up for sale," tweeted the Labour Party. "It's time to save the NHS from a U.S. trade deal. You can't trust the Tories with our NHS."
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.